<DOC>
	<DOCNO>NCT01838655</DOCNO>
	<brief_summary>Background : - Oculocutaneous albinism , type 1B ( OCA1B ) genetic disease cause problem gene make tyrosine . Tyrosine amino acid need produce pigment skin , hair , eye . People OCA1B pale skin , white hair , light-colored eye . Pigment back eye help vision , people OCA-1B often visual problem . Researchers want see drug call nitisinone help improve eye pigmentation vision people OCA1B . Nitisinone approve treat relate genetic disease cause problem tyrosine , may help people OCA1B . Objectives : - To see nitisinone help improve eye pigmentation vision people OCA1B . Eligibility : - Individuals least 18 year age OCA1B . Design : - This study last 18 month . It require eight outpatient visit , 3 month apart . Each visit require 1 2 day test . - Participants screen physical exam , eye exam , medical history . They additional vision neurological test . They test see brain retinas respond light . They also take hair blood sample , answer question diet . - Participants receive study drug . They take one pill day 1 year . They keep track dose study diary . - At outpatient visit , participant follow test : - Medical history physical exam - Neurological eye exam - Retina function test - Tests skin brain 's response light - Blood urine test - Dietary consultation - Visual function questionnaire . - After end study , participant return care regular eye doctor .</brief_summary>
	<brief_title>Nitisinone Type 1B Oculocutaneous Albinism</brief_title>
	<detailed_description>Objective : The primary objective study evaluate oral nitisinone treatment improve ocular pigmentation adult participant oculocutaneous albinism , type 1B ( OCA1B ) . Secondary objective study determine whether select outcome measure robust enough use large trial ass whether oral nitisinone improve visual function , skin pigmentation , hair pigmentation participant OCA1B . Study Population : Five participant OCA1B enrol initially . However , additional three participant may enrol account participant withdraw study reason Month 12 visit . Design : In pilot , phase 1/2 , single-site , prospective , open label trial , participant receive 2 mg oral nitisinone daily least one year , follow least 18 month . Ocular non-ocular data collect least every three month , first follow-up visit occur three month final baseline visit . Participants require least 8 outpatient visit NEI clinic period 18 month . This study common termination date therefore may continue four year . Outcome Measures : The primary outcome study absolute change iris pigmentation 8-point scale 12 month compare baseline . Participants leave right eye analyze . The absolute change iris pigmentation eye 8-point scale 3 , 6 9 month compare baseline assess secondary outcome . Other secondary outcome eye include absolute percent change semi-quantitative iris pigmentation image analysis ; absolute change electronic visual acuity ( EVA ) ; absolute change contrast sensitivity without glare , medium glare , high glare ; absolute change full-field ERG measure ; absolute percent change melanin content skin use skin reflectometry ; qualitative change hair , skin , fundus pigmentation 3 , 6 , 9 12 month compare baseline . The absolute percent change hair melanin also assess 12 month compare baseline . The number severity adverse event number withdrawal assess safety outcome .</detailed_description>
	<mesh_term>Albinism</mesh_term>
	<mesh_term>Albinism , Oculocutaneous</mesh_term>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>INCLUSION CRITERIA : To eligible , follow inclusion criterion must meet , applicable . 1 . Participant must 18 year age old . 2 . Participant must understand sign protocol inform consent document . 3 . Participant must normal renal function , liver function , platelet count mild abnormality great grade 1 defined Common Terminology Criteria Adverse Events v4.0 ( CTCAE ) . 4 . Any female participant childbearing potential must negative pregnancy test screening must willing undergo pregnancy test immediately prior start investigational product investigational product . 5 . Any female participant childbearing potential male participant able father child must ( partner ) hysterectomy vasectomy , completely abstinent intercourse , must agree practice two effective method contraception take investigational product least two month follow last dose investigational product . Acceptable method contraception include : Hormonal contraception ( i.e. , birth control pill , inject hormone , dermal patch , vaginal ring ) , Intrauterine device , Barrier method ( diaphragm , condom ) spermicide , Surgical sterilization ( tubal ligation ) . 6 . Participant must OCA1B , define ALL ( ad ) follow criterion : 1 . Participant ophthalmic sign symptom albinism , include : Bilateral visual acuity EETDRS EVA letter score less equal 83 ( i.e. , Snellen equivalent 20/25 worse ) attributable pathology . Bilateral iris transillumination see clinical photograph . 2 . Predominant contralateral decussation ganglion cell axon , determine pattern visual evoke potential ( VEP ) . 3 . Participant least one definitive mutation OCA1 gene ( tyrosinase ) . 4 . Participant definitive mutation OCA2 gene . EXCLUSION CRITERIA : Participant pregnant breastfeeding . Participant male AND definitive mutation OA1 gene . Participant follow abnormal laboratory test result : 1 . Serum potassium &lt; 3.0 mEq/L , 2 . Serum CK &gt; 500 U/L , 3 . Hemoglobin &lt; 10.0 g/dL , 4 . White blood cell ( WBC ) count &lt; 3.0 k/microL , 5 . Plasma tyrosine &gt; 150 microM , 6 . ESR &gt; 100 mm/h , and/or 7 . Serum T4 &gt; 15 microg/dL OR Serum T4 &lt; 4 microg/dL . Participant keratopathy . Participant current malignancy . Participant open skin lesion . Participant diet deliberately increase protein intake disproportionate level ( e.g. , Atkins diet ) . The diet must reasonably balance , determined dietician . Participant uncontrolled hypertension , define systolic blood pressure 180 mmHg diastolic blood pressure 95 mmHg . Participant another chronic ocular disease may confound result visual test , agerelated macular degeneration , cataract possible visual significance , uncontrolled glaucoma . Participant drink equivalent two glass wine per day average , history alcohol abuse , severe liver illness . Participant liver &gt; 3 cm right costal margin . Participant muscle disease . Participant currently take medication know cause elevate liver function test include statins/HMGCoA reductase inhibitor ( e.g. , lovastatin , simvastatin ) ; antiepileptic medication ( e.g. , carbamazepine , phenytoin , phenobarbital ) ; tetracycline derivative , use chronically ; acetaminophen , use daily/chronically ; amiodarone ; medication know significant liver toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 13, 2017</verification_date>
	<keyword>Albinism</keyword>
	<keyword>Nitisinone</keyword>
	<keyword>Melanin</keyword>
	<keyword>Vision Loss</keyword>
</DOC>